Genomtec S.A.
Warsaw Stock Exchange GMT.WA
Genomtec S.A. Price to Sales Ratio (P/S) on January 14, 2025: 91,280.05
-
Genomtec S.A. 52-week high Price to Sales Ratio (P/S) is 417,723.79 on December 20, 2024, which is 357.63% above the current Price to Sales Ratio (P/S).
-
Genomtec S.A. 52-week low Price to Sales Ratio (P/S) is 80,994.32 on September 19, 2024, which is -11.27% below the current Price to Sales Ratio (P/S).
-
Genomtec S.A. average Price to Sales Ratio (P/S) for the last 52 weeks is 115,042.54.
| Date | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield |
|---|
| CEO | Mr. Miron Tokarski Ph.D. |
| IPO Date | March 17, 2021 |
| Location | Poland |
| Headquarters | Bierutowska Street 57-59 |
| Employees | 17 |
| Sector | Health Care |
| Industries | |
Genomtec S.A. researches, develops, manufactures, and commercializes innovative molecular diagnostic products in optical systems and isothermal nucleic acid amplification methods in Poland and internationally. The company develops Genomtec ID, a technological device that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analyzing the biological material of patients using swabs, urine samples, saliva, blood, and other body fluids. It also develops Genomtec Tumor, a SNAAT based solution used to identify neoplastic mutations and mutations with prognostic value in neoplastic disease; Genomtec SARS-CoV-2 EvaGreen and Direct-RT-LAMP CE-IVD Kit to detect SARS-CoV-2 RNA in various biological samples from patients with suspected COVID-19 infection; and Genomtec RT-LAMP CE-IVD Duo-Kit for the detection of all variants of the SARS-CoV-2 virus. Genomtec S.A was founded in 2016 and is based in Wroclaw, Poland.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email